Non-posttransplant lymphoproliferative disorder malignancy after hematopoietic stem cell transplantation in patients with primary immunodeficiency: UK experience - 06/06/18
Doi : 10.1016/j.jaci.2018.02.038
Mohamed Najib Mohamed Unni, MMED a, Reem Elfeky, MD b, Kanchan Rao, MD b, Zohreh Nademi, PhD a, Robert Chiesa, MD b, Persis Amrolia, PhD b, Roderick Skinner, PhD a, Olga Slater, PhD b, Austen Worth, PhD b, Terence Flood, MD a, Mario Abinun, MD a, Sophie Hambleton, DPhil a, c, Waseem Qasim, PhD b, Hubert B. Gaspar, PhD b, Andrew J. Cant, MD a, Andrew R. Gennery, MD a, c, Paul Veys, MD b, Mary A. Slatter, MD a, c 
a Children's Haemopoietic Stem Cell Transplant Unit, Great North Children's Hospital, Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
b Great Ormond Street Hospital NHS Trust, London, United Kingdom
c Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
| Disclosure of potential conflict of interest: R. Elfeky reports employment with Bellicum Pharmaceutical running phase I/II trials with BPX-501. A. Worth reports institutional grants pending from the National Institute of Health Research, Wellcome Clinical Research, and the GOSH Childrens Charity; institutional payments for advisory board work for BioTest UK; employment as an immunology consultant at the Great Ormond Street Hospital; and receiving fees for a commissioned review article for the British Journal of Haematology. S. Hambleton reports institutional consultant fees from UCB Celltech and has grants pending from the Jules Thorn Trust and the Wellcome Trust; speaking fees from BioTest; and travel support from the Medical Research Council, the Wellcome Trust, ESID, BSI, UKPIN, Harvard Medical School, the National Institutes of Health, and Oxford University. W. Qasim reports institutional grant funding from the National Institute for Health Research; consultancy fees from Autolus Ltd and to his institution from Servier; and CAR Advisory Board membership at Novartis. Hubert B. B. Gaspar reports board membership and consulting work for Orchard Therapeutics outside the scope of this study. P. Veys reports consultancy fees from Novartis and JAZZ Pharma. The rest of the authors declare that they have no relevant conflicts of interest. |
Crown Copyright © 2018
Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 141 - N° 6
P. 2319 - juin 2018 Retour au numéro
Article précédent
- The parasitic 68-mer peptide FhHDM-1 inhibits mixed granulocytic inflammation and airway hyperreactivity in experimental asthma
- Akane Tanaka, Venkata Sita Rama Raju Allam, Jennifer Simpson, Natalia Tiberti, Jenna Shiels, Joyce To, Maria Lund, Valery Combes, Sinead Weldon, Cliff Taggart, John P. Dalton, Simon Phipps, Maria B. Sukkar, Sheila Donnelly
- Additional oral food challenge considerations
- J. Andrew Bird, David M. Fleischer, Marion Groetch, Anna Nowak-W?grzyn, Scott Sicherer, Michael C. Young
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?